Clinical trial
A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma
NCT02759601 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma
- Lead sponsor
- Queen Mary University of London
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 31, 2013
- Completion date
- December 31, 2018
- Enrollment
- 69 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma